Systemic Tofacitinib in Alopecia Areata: A Single Center Retrospective Descriptive Cohort Study

This retrospective study assessed the effectiveness of systemic tofacitinib in treating alopecia areata in 45 patients, finding that 77.78% experienced satisfactory improvement, with significant hair regrowth in 28 patients. The treatment was generally well-tolerated, with dyslipidemia as the most common mild side effect in 37.76% of patients. The study suggests better outcomes with early-age treatment and shorter disease duration. However, it notes limitations such as its retrospective design and small sample size, recommending larger, prospective studies for further evaluation of long-term efficacy and safety.